Clinical Efficacy of Ulinastatin Combined with Meglumine Cyclic Adenosine Monophosphate in the Treatment of Viral Myocarditis and its Effect on Related Apoptotic Molecules
GAO Min, XIAO Ming, ZHOU Guo
Shandong Provincial Third Hospital, Jinan Shandong,250031,China
Abstract 【Objective】To investigate the clinical efficacy of ulinastatin combined with meglumine cyclic adenosine monophosphate in the treatment of viral myocarditis (VMC) and its effect on related apoptotic molecules. 【Methods】A total of 106 patients with VMC treated in our hospital were randomly divided into observation group (ulinastatin combined with meglumine cyclophosphate) and control group (meglumine cyclophosphate), with 53 cases in each group. The two groups were treated for 2 weeks. The clinical efficacy, myocardial injury indexes (cardiac troponin I (cTnI), creatine kinase (CK), creatine kinase isoenzyme (CK-MB)), the levels of apoptosis molecules (soluble apoptosis factor (sFas), soluble apoptosis related factor ligand (sFasL)) and the incidence of adverse reactions were compared between the two groups. 【Results】 Tow weeks after treatment, the total effective rate of clinical efficacy in the observation group was 92.45% (49/53), which was significantly higher than 75.47% (40/53) in the control group(χ2=5.68,P=0.017＜0.05).After 2 weeks of treatment, the levels of serum cTnI, CK, CK-MB, sFas and sFasL in the two groups were lower than those before treatment, and the levels in the observation group were lower than those in the control group (P<0.05). The incidence of adverse reactions in the observation group was 11.32% (6/53), which was higher than 5.66% (3/53) in the control group, but the difference was not statistically significant(χ2=0.49,P=0.48＞0.05).【Conclusion】 Ulinastatin combined with meglumine cyclic adenosine monophosphate is effective in the treatment of VMC patients, which can effectively reduce the myocardial injury of patients, which may be related to the inhibition of apoptotic molecules, and the addition of ulinastatin does not significantly increase the adverse drug reactions, which is worthy of clinical reference.
GAO Min,XIAO Ming,ZHOU Guo. Clinical Efficacy of Ulinastatin Combined with Meglumine Cyclic Adenosine Monophosphate in the Treatment of Viral Myocarditis and its Effect on Related Apoptotic Molecules[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(2): 281-283.
2022, Vol. 39 
